期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 125, 期 3, 页码 1329-1338出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI79526
关键词
-
资金
- Paul Barrett Endowed Fellowship at St. Jude Children's Research Hospital
- European Research Council [281600]
- Fund for Scientific Research - Flanders [G030212N, 1.2.201.10.N.00, 1.5.122.11.N.00]
- NIH [AR056296, CA163507, AI101935]
- American Lebanese Syrian Associated Charities (ALSAC)
Leishmaniasis is a major tropical disease that can present with cutaneous, mucocutaneous, or visceral manifestation and affects millions of individuals, causing substantial morbidity and mortality in-third-world countries. The development of a Th1-adaptive immune response is associated with resistance to developing Leishmania major (L. major) infection. Inflammasomes are key components of the innate immune system that contribute to host defense against bacterial and viral pathogens; however, their role in regulating adaptive immunity during infection with protozoan parasites is less studied. Here, we demonstrated that the NLRP3 inflammasome balances Th1/Th2 responses during leishmaniasis. Mice lacking the inflammasome components NLRP3, ASC, or caspase 1 on a Leishmania-susceptible BALB/c background exhibited defective IL-1 beta and IL-18 production at the infection site and were resistant to cutaneous L. major infection. Moreover, we determined that production of IL-18 propagates disease in susceptible BALB/c mice by promoting the Th2 cytokine IL-4, and neutralization of IL-18 in these animals reduced L. major titers and footpad swelling. In conclusion, our results indicate that activation of the NLRP3 inflammasome is detrimental during leishmaniasis and suggest that IL-18 neutralization has potential as a therapeutic strategy to treat leishmaniasis patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据